Background: Glanzmann thrombasthenia (GT) is an inherited autosomal recessive platelet disorder characterized by a complete or partial lack, or mutation, of the GPIIb/IIIa complex (integrin α IIb β 3 ) on the thrombocytes' surface, leading to a severe bleeding syndrome. Material and Methods: Molecular genetic analysis was performed in patients with suspected GT. The aim of the present study was the identification of new natural variants, their impact on platelet function, and their relation to the risk of bleeding. Results: Expression of the platelet integrin α IIb β 3 was determined by flow cytometry. Mutations were identified through sequencing of cDNA and genomic DNA. In addition, platelet function studies (PAC-binding, aggregations) were implemented. The study included 25 patients revealing 13 mutations (GPIIb: n = 9; GPIIIa: n = 4). Two of the 13 mutations were previously described (T207I; L214P). The remaining mutations have not been published yet, whereas 1 mutation in 2 unrelated families was identical (3062 T→C). Conclusion: All patients with less than 25% of present α IIb β 3 have a medical history of bleeding.
Introduction
Glanzmann thrombasthenia (GT) is a rare, recessively inherited, bleeding syndrome affecting the megakaryocyte lineage [1, 2] . Affected patients exhibit a lifelong moderate to severe bleeding tendency with mainly mucocutaneous bleeding. The thrombasthenic phenotype is linked to quantitative and/ or qualitative abnormalities in the platelet fibrinogen receptor, the α IIb β 3 integrin (glycoprotein (GP) IIb/IIIa, CD41/ CD61), which mediates the incorporation of platelets into an aggregate or thrombus at sites of vessel injury [3] . Laboratory parameters in severe GT show normal platelet count, prolonged bleeding time, absence of platelet aggregation in response to multiple physiologic agonists, and impaired adhesion to siliconized glass. The more common heterozygous GT patients show almost normal or slightly diminished platelet aggregation.
The α IIb (ITGA2B) and β 3 (ITGB3) genes are located on chromosome 17 (q21-22). ITGA2B spans 17 kb and comprises 30 exons, ITGB3 spans 46 kb and has 15 exons. The fibrinogen binding site of the receptor complex seems to be a discontinuous surface made up of various regions of both subunits. Fibrinogen binding to activated α IIb β 3 induces further sequential conformational changes in the receptor complex, inducing exposition of cryptic ligand-binding sites with outside-in signal transduction processes and cytoskeletal rearrangement [4] . The exact course of events is not known but various regions in the α IIb and β 3 subunits are known to be involved in fibrinogen binding [5] [6] [7] [8] [9] [10] [11] [12] .
GT is classified into 3 subtypes, depending on the level of present α IIb β 3 . Patients with type I or classical GT are homozygous for the disease and have a virtual absence of α IIb β 3 (<5% of normal level). Type II GT patients can have up to 25% of the normal level. In the variant type, α IIb β 3 levels are near normal but functionally impaired, leading to defective binding of fibrinogen [13] . Heterozygotes for type I GT have approximately 50% of the normal level of platelet α IIb β 3 , without bleeding problems. Since the cloning of the α IIb and β 3 genes, a number of mutations have been found to be associated with GT. A continually updated database is available on the Internet (sinaicentral.mssm.edu/intranet/research/glanzmann); it currently lists 103 records of mutations in the α IIb and 68 records of mutations in the β 3 gene. The types of mutations identified in both genes include minor and major deletions, insertions, inversions, and mostly point mutations. The molecular and functional characterization of many of them has provided important information about the biosynthesis and structure-function relationships of the α IIb β 3 complex as well as the biology of other molecules of the integrin family [14, 15] .
Most of the documented single nucleotide substitutions are located in the coding sequence and cause missense or nonsense substitutions at the amino acid level, producing either normal-sized non-functional or truncated proteins [16] [17] [18] [19] [20] .
Pillitteri/Pilgrimm/Kirchmaier Amplification of Genomic DNA by PCR and Synthesis of cDNA Amplification of all individual exons of the α IIb and β 3 genes, including splicing sites, was performed by using primers located in the flanking intron regions. Table 2 provides information about the length and location of all used primers. According to the different primers, polymerase chain reactions (PCRs) were performed using different annealing temperatures varying from 50 to 62 °C for 30 s to optimize the amplification products. Extension was performed at 72 °C for 60 s using Hot Start Taq Plus polymerase (Qiagen) for all exons. The amplification contained 35 cycles and was followed by a 5-min final extension step at 72 °C. Amplified DNA fragments were purified using QIAquick PCR Purification kit (Qiagen) according to the manufacturer's instructions. Platelet mRNA was reverse transcribed using the cDNA Synthesis System Plus (Amersham International, Little Chalfont, UK) as previously described [28] .
Nucleotide Sequence Analysis
Cycle sequencing of the entire α IIb and β 3 DNA was accomplished by using the primers from table 2 and the BigDye ® Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. cDNA sequencing of α IIb and β 3 was performed with overlapping primers (sequences not shown). The cycle sequencing products were purified by using DyeEx 2.0 Spin kit (Qiagen) pursuant to the manufacturer's instructions. Analysis of the sequencing products was executed in ABI Prism 310 (Applied Biosystems) sequencer utilizing Performance Optimized Polymer 6 (Applied Biosystems) and ABI Prism Genescan software (Applied Biosystems). The regions containing the mutation were sequenced 3 times in both directions. crobeads (Calibrite beads; BD Bioscience) were used each day for standardization of the instrument settings. To study platelet GPIIb/IIIa activation and fibrinogen binding by flow cytometry, platelets in PRP were activated with either adenosine diphosphate (ADP, 10 μmol/l) or thrombin receptor-activating peptide (TRAP-6, 10 μmol/l) in the presence of saturating concentrations of FITC-conjugated PAC-1 (directed against activated α IIb β 3 ) or anti-fibrinogen mab. Following incubation for 15 min at room temperature, platelets were fixed for 15 min, washed with CellWash, and analyzed in a final volume of 400 μl for cell-bound fluorescence in the flow cytometer. The background was measured using FITC-conjugated anti-mouse IgG.
Light Transmission Aggregometry
Light transmission aggregometry (LTA) was performed on the APACT 4S Plus aggregometer (LABiTec, Ahrensburg, Germany). Platelet counts were not adjusted, and the baseline optical density was set with PPP. The used inducers were ADP (final concentrations: 2.5, 5, 10 μmol/l), collagen (0.5, 1, and 2 μg/ml; Horm ® Nycomed Austria GmbH, Linz, Austria), epinephrine (10 μmol/l final concentration), and arachidonic acid (0.75 mol/l final concentration). Optical density changes were recorded photoelectrically for 7 min as platelets began to aggregate. The aggregation response is given as percentage of maximal light transmission (Amax).
DNA and RNA Extraction DNA isolation from whole blood was carried out by using the QIAamp DNA Blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Total RNA in platelets was isolated from PRP as previously described [28] . Pillitteri/Pilgrimm/Kirchmaier found to be compound heterozygous with both mutations located in the β 3 gene (table 5) . In 14 patients, only a mutation in the heterozygous state was found and no additional gene defect was identified. We assume that 3 out of those 14 hetero zygotes are compound heterozygous (GE, SB, WC), however the second mutations could not yet be located. To exclude that the mutations found in our patients represent common polymorphisms, 50 randomly chosen samples from different ethnic or geographic backgrounds were screened for all mutations. None of these subjects were found to carry one of the mutations.
Missense Mutations (n = 4)
Two missense mutations were detected within the α IIb gene (table 3) . In exon 5, a homozygous Thr 207 to Ile (ACT→ATT)
Results

Molecular Analysis of α IIb and β 3 Transcripts
To determine the molecular basis underlying the abnormalities of α IIb β 3 receptor in the patients, full-length α IIb and β 3 (1-2 kb fragments) from the patients' platelets were amplified using PCR and sequenced by a modified Sanger method. A list of mutations identified within the α IIb and β 3 genes is shown in tables 3 and 4. We found 8 different mutations of the α IIb gene in 20 patients and 4 mutations of the β 3 gene in 5 patients. Four missense mutations, 4 splicing site mutations, 2 insertions of a single nucleotide, 1 deletion of a single nucleotide, and a deletion of 2 nucleotides were found. Overall, 9 patients were homozygous for a mutation in the α IIb gene (n = 7) or in the β 3 gene (n = 2), whereas only 1 patient was Nucleotide nomenclature is italicized and refers to splicing site and frameshift mutations whereas the amino acid nomenclature is nonitalicized referring to point mutations causing an amino acid exchange.
Pillitteri/Pilgrimm/Kirchmaier
Splicing Site Mutations (n = 4)
All splicing site mutations were found in the α IIb gene (table 3) . Sequencing of exon/intron regions using genomic DNA revealed a homozygous splicing donor site mutation (3060G→A) in exon 29 in 2 siblings (TA, TG). Analysis of the entire cDNA showed a homozygous deletion of exon 29 in the α IIb subunit, the putative transmembrane region. As expected, both parents (TN, TF) were heterozygous carriers of that mutation. A further homozygous splicing donor site mutation (3062T→C) was found in exon 29 (LN) and as heterozygous condition in the patients' parents (LH, LB). In addition, this splicing site mutation (3062T→C) was also detected, as heterozygous condition, in an additional patient (SB). Although no blood relationship was reported, these 2 patients were from the same region in Germany. Moreover, homozygous splicing donor site mutations in exon 17 (1754T→C) (DZ) or exon 18 (1878G→C) (HM) were identified.
Polymorphisms (n = 5)
Relating to GT, there are various single nucleotide polymorphisms known in α IIb and β 3 , which can lead to an amino acid exchange but have no impact on the function of the thrombocytes in terms of aggregation or adhesion ability. The investigation of all patients revealed previously described polymorphisms in homozygous and heterozygous forms concerning several patients (DZ, WC, TE, YF, PJ). The polymorphism Ile843Ser in the α IIb subunit could be identified in 2 patients (WC: heterozygous; TE: homozygous). The β 3 subunit contains occurs also in the β-propeller domain and involves substitution from an aliphatic amino acid to heterocyclic amino acid. In the β 3 gene, the heterozygous missense mutation (Gly 286 Arg) lies, according to the known crystal structure [29] , in a highly conserved position within a proposed intramolecular disulfide loop, between Cys 232 and Cys 273 [30] . Furthermore, a heterozygous Leu 684 (CTG→CGG) to Arginin substitution was found in 2 related patients (GE, CM).
Deletions (n = 2)
Two mutations were detected within the β 3 gene (table 3) . A homozygous deletion at Gly 517 in exon 10 (1550delG) leads to changes of the corresponding amino acids of exon 10. In addition, a homozygous deletion of 2 nucleotides in exon 13 (2068delGT) is predicted to lead to changes of the corresponding amino acids of exon 13 and to a premature stop codon at position 696.
Insertions (n = 2)
Two mutations were detected within the α Ib gene (table 3) . A heterozygous insertion at Ala744 (2232Gins) in exon 22 is predicted to lead to changes in the corresponding amino acids, and was detected in 2 affected blood relatives (WC, WV). One insertion mutation was located within the β 3 gene (table  3) , and was found in the heterozygous state at Ile377 in exon 9 (1129Ains) in 2 related patients. This mutation would lead to changes in the corresponding amino acids encoded by the subsequent portion of exon 9. Novel Mutations in the GPIIb and GPIIIa Genes in Glanzmann Thrombasthenia 275 tive substitutions in strictly conserved residues among vertebrates in both genes. Two of the point mutations in α IIb , Thr 207 to Ile and Leu 214 to Pro, are located in the FG-GAP 3 of the β propeller. Leu 214 to Pro has already been described by Grimaldi et al. [31] . It has been shown that the FG-GAP is important for ligand binding, so the Leu 214 to Pro mutation disrupts the structural conformation and impairs the ligandbinding properties of the heterodimeric complex. Additionally, the mutation seems to confer susceptibility to proteolysis [31, 32] . Concerning the Thr 207 to Ile mutation, it has been described to impair fibrinogen binding and affect the expression of α IIb β 3 on the platelet surface [28] . Further, we found a point mutation at position 684 leading to a Leu to Arg substitution. This mutation is located in the calf-1 domain of exon 20, also in the α IIb subunit. The calf-1 domain creates minor interfaces with the β 3 subunit [33] . Therefore, conformational changes due to this amino acid substitution could impede contact between α IIb and β 3 resulting in a failure of complex-formation. If the subunits do not form a complex, the protein subunits are not protected from intracellular proteolysis, and therefore they cannot be anchored in the cell membrane. Gly 286 to Arg is located in the VWFA domain, also called βA domain, of the β 3 subunit. The βA domain is a ligandbinding head region of the β subunit. Conformational changes in VWFA have an impact on the ligand-binding activity, and ligand recognition also causes conformational changes transduced from this domain [34] .
In 5 unrelated individuals and their relatives we detected splicing site defects. Three of those splicing site mutations are located in the splicing donor site in exon 29, and 2 of them (3062T→C; SB, LN) are even identical although no apparent consanguinity was reported. However, both patients were from the same region in Germany. Both of those splicing site mutations lead to a complete loss of exon 29, which was proven by cDNA sequencing. The mutations are located in the cytoplasmatic domain proximal to the transmembrane region in the N-terminal area of the GFFKR motif. Regions proximal to the transmembrane domains of the α and β subunits contain highly conserved sequences, such as the GFFKR motif referring to the α IIb subunit, and are found to be important for maintaining the inactive low-affinity state of the integrin. It is confirmed that the cytoplasmatic domains are essential for the formation of the heterodimer, and the GFFKR motif appears to be required for association of the α and β subunits [35, 36] . The 3062T→C substitution at position V1021 is located at only 1 amino acid prior to the start of the GFFKR motif and leads to an alternative splicing. Therefore, it could be assumed that due to the alternative splicing, N-terminal to the motif, the conformation of the protein is changed in such a way that it could be impossible for the above-mentioned motif to associate with the corresponding motif in the β 3 subunit.
The other two splicing site defects were detected in exons 17 and 18 of the α IIb subunit. The 1754T→C (DZ) substitution situated in the splicing donor site of exon 17 is located in the thigh more polymorphisms. Patients DZ and YF show the Leu33Pro polymorphism in the homozygous and patient SB in the heterozygous form. Furthermore, the polymorphisms Val381Val (TE: heterozygous; PJ: homozygous) and Arg489Gln (TE: heterozygous; PJ: homozygous) could be ascertained. The possibility of a founder effect for the mutations V585G, 2232Gins, V1021A, G286A + 1129Ains, 1550delG, and 2068delGT seems unlikely but cannot be excluded because the patients carrying polymorphisms all seem to suffer from GT type I, except for one. However, a coherency is not established.
Platelet Function Studies
The results of flow cytometric and platelet aggregation studies are summarized in table 6. As expected, platelets from patients with type I GT (0-5% of α IIb β 3 on platelets: TA, TG, GE, TE, LN, HM, OK, MM, WC, PJ) were unable to aggregate in response to ADP (5 μmol/l) and collagen (1 μg/ml). Platelets of these patients failed to aggregate even with higher concentrations of ADP (10 μmol/l) and collagen (2 μg/ml) (data not shown). Furthermore, analysis of α IIb β 3 activationdependent epitope using flow cytometry showed that mab PAC-1 was unable to bind after activation with TRAP or ADP (table 6) . However, a larger variability was seen between the different tests in patients with >20% of α IIb β 3 on platelets. For example, the heterozygous parents of TE and TG had a normal amount of α IIb β 3 and slightly inhibited platelet aggregation but showed distinct inhibition of PAC-1 binding. The parents of patient WC also showed normal α IIb β 3 expression on platelets. PAC-1 binding was markedly decreased with a more pronounced effect for the mother's platelets. Surprisingly, the father's platelets were unable to aggregate in response to ADP and collagen. In the mother, we observed a markedly decreased platelet aggregation response to ADP and collagen. Patient SB had a residual α IIb β 3 surface expression of 23%. Functional analysis of α IIb β 3 revealed low PAC-1 binding capacity of about 10% after activation with ADP or TRAP. These results indicate that both a quantitative and qualitative abnormality in the α IIb β 3 receptor exist in this patient.
Discussion
GT is a rare congenital bleeding syndrome which results in deficient platelet aggregation due to the absence or dysfunction of the fibrinogen receptor α IIb β 3 . Due to the dimension and diversity of the occurring mutations in α IIb β 3 , it is rather complex to identify mutations that are responsible for GT. In the present study, 10 novel and 2 previously described gene alterations that are known to cause GT were identified in 12 unrelated patients (table 3) and their first-degree relatives. To ascertain the mutations, we sequenced the coding regions of the α IIb and β 3 subunits including the exon/intron boundaries. Our study revealed 4 point mutations which are all non-conserva- Pillitteri/Pilgrimm/Kirchmaier identify 2 patients with deletions within the β 3 subunit. A deletion of 1 nucleotide (1550delG) was detected in exon 10 of β 3 . This deletion is situated in the EGF-2 domain and does not lead to a premature stop codon, nevertheless we assume that the nearby located disulphide bond can not be formed due to a modified amino acid sequence. The EGF domains are cysteine-rich modules, containing multiple disulphide bonds. In particular, the EGF-2 region is wedged in the bent between integrin stalk and headpiece domains, poised to communicate structural rearrangements between the cytoplasmic domains and the ligand-binding headpiece [38] . Also located in β 3 , a 2-nucleotide deletion (2082delGT) was identified in exon 13, affecting the β-tail domain (β-TD). This mutation leads to premature termination of the translation at amino acid position 696 and therefore to a truncated protein.
Several of these patients were carrier of diverse polymorphisms (table 6) . We cannot exclude founder effects of polymorphisms regarding the newly revealed mutations in α IIb and β 3 but it seems improbable. Solely in 3 heterozygous patients, a second mutation forming the compound heterozygous status could not yet be detected. A genotype/phenotype correlation is only vaguely viable. Therefore, a profound genotype/phenotype coherence could not be implemented. However, we came to know that the patients with splicing site defects suffer from mild to moderate bleeding, whereas point mutations and insertions/deletions tendencially result in moderate to severe bleeding. In conclusion, our investigation of several patients, and in some cases including their first-degree relatives, revealed a number of different mutations within the α IIb and β 3 subunits associated with causing GT. This vast number of different mutations indicates the genetic heterogeneity in the studied group as well as in GT in general.
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domain of the α IIb subunit. The thigh domain has substantial contact with the β-propeller. Losonczy et al. [37] previously suggested that this contact might be important for the proper orientation of the β-propeller to interact properly with the β3 subunit. An alteration in this domain could therefore change the orientation of the β-propeller and inhibit complex formation with the β 3 subunit [37] . The homozygous splicing donor site mutation 1878G→C (HM) affecting exon 18 is situated in the calf-1 domain of the GPIIb subunit. The calf-1 and calf-2 domains form minor interfaces with GPIIIa [36] . Rosenberg et al. [33] formerly published that significant changes in the calf-1 and calf-2 domains do not avert complex formation of α IIb β 3 but affect its transport to the cell surface, probably by its retention and subsequent degradation in the endoplasmic reticulum [33] . We assume that due to the found splicing site defects, the affected exons are non-existent and the concerned domains are thereby sustainably influenced in their conformations.
In 4 GT patients, we found frameshift mutations caused by insertions or deletions. Three out of 4 are situated in the β 3 subunit. Insertions or deletions lead to a shift in the reading frame and often cause a premature stop codon resulting in premature termination of the protein or an abnormal protein product with an incorrect amino acid sequence.
In 1 patient, we could identify a heterozygous insertion of G at nucleotide position 2232. This frameshift does not result in a premature stop codon but the amino acid sequence is severely altered, probably resulting in an abnormal protein.
Since this mutation is also situated in the calf-1 domain of the α IIb , we assume once more that complex formation is impaired resulting in a premature intracellular proteolysis.
A compound heterozygous patient and his mother showed a heterozygous insertion of A in exon 9 at nucleotide position 1129. This insertion results in a stop codon at amino acid position 380, probably leading to premature termination. Here, the hybrid domain is affected.
Concerning frameshift mutations we could additionally
